Genelux posts wider-than-expected Q2 loss on higher R&D expenses
GNLX•Outlook and trial timeline
Genelux expects topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer trial in the second half of 2026.
The company also anticipates additional dose-escalation updates from systemic Olvi-Vec studies in 2026.
Genelux expects cash and equivalents to fund operations into the first quarter of 2027.
Q2 loss widens as R&D expenses rise
Genelux posted a wider-than-expected second-quarter net loss as higher research and development expenses pushed operating results below analyst estimates.
The US immuno-oncology firm said its Q2 net loss widened, missing analyst expectations, and income from operations also missed estimates. Operating expenses rose due to higher Phase 3 trial costs.
Key quarterly figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | Miss | $9.47 mln | $8.77 mln (6 Analysts) |
| Q2 Income from Operations | Miss | -$9.65 mln | -$8.95 mln (6 Analysts) |
| Q2 Operating Expenses | $9.65 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for Genelux Corporation is $16.00, about 492.6% above its August 12 closing price of $2.70.
